World Leaders in Proteomics and Genomics to Convene at the 2nd International Top-Down Proteomics Symposium
2023 International Top-Down Proteomics Symposium Building the bridge from genotype to phenotype, the Symposium will…
Logistics
Intelligent Bio Solutions Completes Critical Development Milestone in Plans to Add Ketamine and Tramadol to Fingerprint Drug Test
New assays for ketamine and tramadol testing pass initial Intelligent Fingerprinting design phase and begin…
Intelligent Bio Solutions Completes Critical Development Milestone in Plans to Add Ketamine and Tramadol to Fingerprint Drug Test
New assays for ketamine and tramadol testing pass initial Intelligent Fingerprinting design phase and begin…
SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023
Press release – No. 11 / 2023 SAVE THE DATE: Zealand Pharma to host Obesity…
BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell
BioStem Technologies Lovell® Government Services PENSACOLA, FL, Sept. 06, 2023 (GLOBE NEWSWIRE) — Lovell® Government…
BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell
BioStem Technologies Lovell® Government Services PENSACOLA, FL, Sept. 06, 2023 (GLOBE NEWSWIRE) — Lovell® Government…
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is…
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is…
Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
FDA issues Complete Response Letter (CRL) for ONS-5010 BLA based on CMC and need for…
Biomerica Reports Fiscal 2023 Year End Results
Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed…
Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock
SAN DIEGO and GAINESVILLE, Ga., Aug. 24, 2023 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal”;…
Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock
SAN DIEGO and GAINESVILLE, Ga., Aug. 24, 2023 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal”;…
Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights
– Combined full-year revenue and government support income increased 355% year-over-year – – Received guidance…
Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights
– Combined full-year revenue and government support income increased 355% year-over-year – – Received guidance…
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg…
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg…
Avicanna Reports Q2 2023 Financial Statement
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
Avicanna Reports Q2 2023 Financial Statement
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an…
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an…